MedPath

The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)

Completed
Conditions
Myocardial Infarction
Registration Number
NCT00430612
Lead Sponsor
Northwestern University
Brief Summary

The purpose of the PACE-MI (OBTAIN) registry is:

* Analyze beta-blocker dose response effect on outcome over two years

* Explore gender and minority differences in beta-blocker utilization and outcomes.

In patients with Myocardial Infarction (MI) discharged from the hospital, beta-blocker dose will be predictive of survival.

Exploratory analyses: Gender and racial effects-gender and race are, similarly, hypothesized to be predictive of post-MI survival.

The existence of interactions between gender and beta-blocker effect as well as race and beta-blocker effect will also be evaluated.

Detailed Description

Methods

All patients admitted to the coronary care areas with an acute myocardial infarction will be entered into the registry. At the time of discharge from the coronary care unit, clinical data will be entered. The registry will include approximately 6800 patients.

As there is no intervention in the registry, the data to be collected are standard for quality assurance purposes and cannot practicably be carried out without waivers of consent and HIPAA authorization, there will be no consent specifically for registry patients at baseline. Systems have been implemented to ensure the registry data will remain confidential. Sites have received IRB approval of waiver of consent and HIPAA for the baseline registry data.

Data to be collected will include demographic (including ethnic and race classifications according to NIH guidelines) data and information regarding the index myocardial infarction. Use of beta-blockers at discharge from the coronary care unit will be documented. In addition, beta-blocker use at hospital discharge will be noted. Data for the registry will be obtained from ER notes, admission notes, cardiac catheterization lab reports, medication lists, lab reports, and discharge summaries.

Follow-Up

Follow-up for registry patients will be conducted at year 1 and year 2 post-myocardial infarction. Data may be obtained via medical chart review, phone contact, and Social Security Death Index (SSDI). For follow-up information obtained via chart review or the SSDI, a detailed justification for waiver of HIPAA and consent requirements is attached to this protocol. If phone contact is required with the patient, we are suggesting the following process:

* A letter should be sent out to the patient approximately one week prior to the contact in which the rationale for the study will be provided, as well as a delineation of the patient's right to participate or not to participate (by either providing or not providing the requested information).

* At telephone contact with the patient, the coordinator will document whether the patient consents to provide the information. If the patient consents, the coordinator will proceed to obtain the requested information.

* In the event that the participating institution's IRB requires a written, signed consent for this verbal contact, a written consent form template is provided.

Data collected at follow-up interview will include vital status, beta-blocker use, other cardiac medications and any cardiovascular hospitalizations.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
7057
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total mortality at 2 years post myocardial infarctionMeasured at Years 1 and 2

Compare Kaplan Meier survival curves for the following 5 beta-blocker dose groups:

No beta-blockers - 12.5% (\>0 - 12.5%) 25% (\>12.5 - 25%) - 50% (\>25 - 50%) Full Dose (\>50%)

Secondary Outcome Measures
NameTimeMethod
Total mortality - secondary analysisMeasured at Year 1 and Year 2

Compare Kaplan-Meier survival curves for the following 2 beta-blocker dose groups:

Very Low Dose (\>0-25%) vs. High Dose (≥50%)

Trial Locations

Locations (23)

Little Rock Cardiology Clinic

🇺🇸

Little Rock, Arkansas, United States

MemorialCare Heart and Vascular Institute - Long Beach Memorial Medical Center

🇺🇸

Long Beach, California, United States

West Los Angeles VA Medical Center

🇺🇸

Los Angeles, California, United States

Bridgeport Hospital

🇺🇸

Bridgeport, Connecticut, United States

Baptist Cardiac and Vascular Institute

🇺🇸

Miami, Florida, United States

Orlando Regional Medical Center

🇺🇸

Orlando, Florida, United States

Northwestern Memorial Hospital

🇺🇸

Chicago, Illinois, United States

Clarian Health/Methodist Research Institute

🇺🇸

Indianapolis, Indiana, United States

Henry Ford Hospital

🇺🇸

Detroit, Michigan, United States

Park Nicollet

🇺🇸

Saint Louis Park, Minnesota, United States

Scroll for more (13 remaining)
Little Rock Cardiology Clinic
🇺🇸Little Rock, Arkansas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.